Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 2/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | PDE1A | P54750 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18061466 | 0.87 | PDE1B (0.50) | PDE1BPDE1APDE1CMEN1KMT2A | |
| SCHEMBL7450635 | 0.85 | CNR1 (0.40) | PDE1BGRM2CNR1HTTHPGD | |
| SCHEMBL18061468 | 0.85 | PDE1B (0.57) | PDE1BGRM2PDE1AMEN1KMT2A | |
| SCHEMBL7448044 | 0.84 | CNR1 (0.42) | PDE1BGRM2CNR1HTTHPGD | |
| SCHEMBL3087681 | 0.81 | PDE1B (0.55) | PDE1BGRM2PDE1APDE1CMEN1 | |
| SCHEMBL674429 | 0.74 | ALDH1A1 (0.43) | GRM2SMN1; SMN2NPBWR1ADORA3ALDH1A1 | |
| SCHEMBL676359 | 0.74 | PDE1B (0.42) | PDE1BGRM2PDE1APDE1CMEN1 | |
| SCHEMBL7453613 | 0.73 | GRM2 (0.39) | GRM2CNR1HTTHPGD | |
| SCHEMBL674937 | 0.73 | PDE1B (0.37) | PDE1BGRM2PDE1APDE1CMEN1 | |
| SCHEMBL18061465 | 0.72 | PDE1B (0.57) | PDE1BPDE1APDE1CMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434730-B2 | PDE1 inhibitor compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434730-B2 | PDE1 inhibitor compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434730-B2 | PDE1 inhibitor compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20130338124-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-2575817-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011153136-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338124-A1 | ORGANIC COMPOUNDS | OPRD1, PDE5A, PDE2A | PDE1B 93/4885GRM2 234/4885CNR1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.